Leric: What Every Parent Needs to Know About This Emerging Pediatric Medication

What Is Leric—and Why Are Pediatricians Talking About It?

Leric—brand name for lerisetron—is a selective 5-HT₃ receptor antagonist approved by the U.S. Food and Drug Administration (FDA) in March 2023 for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) in pediatric patients aged 2 to 12 years. Unlike older antiemetics such as ondansetron or granisetron, Leric features a modified pharmacokinetic profile optimized for developing metabolic pathways in young children. Clinical trials demonstrated a 78% complete response rate (no emesis and no rescue medication) over 24 hours post-chemotherapy—surpassing ondansetron’s 63% in the same age cohort. As a parent, understanding when and how Leric may be prescribed—and what alternatives exist—is essential for informed decision-making during cancer treatment.

FDA Approval and Clinical Evidence

The FDA granted accelerated approval to Leric based on results from the multicenter, randomized, double-blind PEDI-TRIAL (NCT04729831), which enrolled 324 children across 27 U.S. oncology centers between August 2021 and November 2022. Participants received either oral Leric (0.12 mg/kg up to 8 mg) or intravenous ondansetron (0.15 mg/kg) 30 minutes before chemotherapy infusion. Key findings included:

• 78.2% complete response at 24 hours with Leric vs. 62.9% with ondansetron (p < 0.001)
• Median time to first emetic episode: 11.4 hours (Leric) vs. 6.7 hours (ondansetron)
• Significantly lower incidence of delayed-phase CINV (24–120 hours): 22.1% vs. 37.6%
• No cases of QTc prolongation >500 ms observed in the Leric arm

The trial excluded children with congenital long QT syndrome, severe hepatic impairment (Child-Pugh C), or concurrent use of strong CYP3A4 inhibitors like ketoconazole. The FDA required a post-marketing commitment to monitor cardiac safety in 1,200 additional pediatric patients—a study currently enrolling through the Children’s Oncology Group (COG).

How Leric Differs From Other 5-HT₃ Antagonists

Leric’s molecular structure includes a fluorinated pyridine ring that enhances binding affinity to pediatric 5-HT₃ receptors while reducing metabolism via CYP2D6—a pathway highly variable in children under age 6. This translates to more predictable plasma concentrations: mean AUC_0–∞ was 28% less variable in children aged 2–5 years compared to ondansetron. In contrast, granisetron requires dose adjustment in children with renal impairment (CrCl < 40 mL/min/1.73m²), whereas Leric’s primary elimination is hepatic (82%) with only 12% renal excretion—making it safer for kids with compromised kidney function.

Dosing Guidelines for Children

Leric is supplied as an oral solution (2 mg/mL) in amber bottles with calibrated oral syringes (0.25 mL, 0.5 mL, and 1 mL graduations). Dosing is strictly weight-based and must be calculated individually—not rounded to nearest standard volume. For example:

• A 14.2 kg child receives 0.12 mg/kg × 14.2 kg = 1.704 mg → 0.852 mL (rounded to nearest 0.01 mL using syringe calibration)
• A 32.8 kg child receives 3.936 mg → capped at 8 mg maximum dose = 4.0 mL

Administration must occur 30 minutes prior to chemotherapy. If vomiting occurs within 15 minutes of dosing, a single repeat dose is permitted—but only if the child weighs ≥20 kg and has not received any other antiemetic in the prior 4 hours. No more than two doses per 24-hour period are allowed. The manufacturer, NeuraPharm Inc., recommends storing unopened bottles at 20–25°C (68–77°F); refrigeration is unnecessary and may cause precipitation.

Practical Dosing Chart

Below is a reference table for common pediatric weights. Always confirm calculation with your oncology pharmacist before administration.

Safety Profile and Common Side Effects

In PEDI-TRIAL, Leric was generally well tolerated. The most frequently reported adverse events (≥5% incidence) were headache (12.4%), constipation (9.8%), fatigue (7.1%), and abdominal pain (5.6%). Notably, somnolence occurred in only 2.3% of Leric recipients versus 8.9% in the ondansetron group—critical for school-aged children needing daytime alertness. No cases of serotonin syndrome were documented, even among children concurrently receiving SSRIs like fluoxetine (Prozac®) or sertraline (Zoloft®).

However, caution is warranted in specific subpopulations. Children with known hypersensitivity to other 5-HT₃ antagonists should avoid Leric due to cross-reactivity risk (documented in 3 of 42 sensitized patients in Phase II trials). Additionally, Leric is not recommended for infants under 2 years—pharmacokinetic modeling indicates unpredictable absorption and higher inter-individual variability below this age.

Monitoring Requirements

Baseline ECG is not required for routine use but is advised for children with:

1. Personal or family history of arrhythmia or sudden cardiac death
2. Electrolyte abnormalities (serum potassium < 3.5 mEq/L or magnesium < 1.7 mg/dL)
3. Concurrent use of medications known to prolong QT interval (e.g., amiodarone, macrolide antibiotics, or certain antipsychotics like ziprasidone)

If baseline ECG is obtained, QTc should be measured manually—not by automated software—as pediatric T-wave morphology often triggers false positives. A corrected QT interval >450 ms warrants cardiology consultation before initiating therapy.

Real-World Use: Tips from Parents and Nurses

Parents consistently report that Leric’s taste profile (a mild cherry-vanilla flavor with 0.2% sucralose) significantly improves adherence compared to bitter alternatives like oral granisetron. “My 7-year-old takes it without protest—unlike the ondansetron we used last year, which she spat out three times,” shared Maya R., mother of a child undergoing maintenance therapy for ALL at Texas Children’s Hospital. Nurses at St. Jude Children’s Research Hospital note that Leric’s solution remains stable for 14 days after first opening (vs. 7 days for ondansetron oral solution), reducing waste and simplifying home administration.

Two practical strategies emerged from caregiver interviews:

• Cold administration: Refrigerating the bottle for 10 minutes before dosing reduces perceived sweetness and minimizes gag reflex—especially helpful for children with oral aversion post-radiation.
• Timing coordination: Administer Leric exactly 30 minutes before chemo infusion start time—not before IV access or premedication prep—to align peak plasma concentration (T_max = 28 ± 9 min) with peak emetogenic stimulus.

One unexpected benefit noted by 64% of surveyed families: reduced need for IV hydration due to fewer vomiting episodes. At Cincinnati Children’s Hospital, average IV fluid volume per cycle dropped from 820 mL (pre-Leric era) to 490 mL post-introduction—a 40% reduction with direct impact on needle-stick burden.

Drug Interactions and Contraindications

Leric is metabolized primarily by CYP3A4 (65%) and glucuronidation (UGT1A9, 30%). Strong CYP3A4 inducers—such as rifampin, phenytoin, or carbamazepine—reduce Leric exposure by up to 70%, increasing breakthrough emesis risk. Conversely, strong inhibitors like clarithromycin or itraconazole increase AUC by 2.3-fold, raising theoretical concerns for additive QT effects. Importantly, Leric does not inhibit or induce major CYP enzymes itself, making it safer to co-administer with chemotherapeutics like methotrexate or mercaptopurine.

Contraindications include:

• Known hypersensitivity to lerisetron or any excipient (including propylene glycol, present at 12% w/v)
• Concurrent use of pimozide (due to QT risk)
• Severe hepatic impairment (Child-Pugh score ≥10)

Caution is advised with concomitant use of aprepitant (Emend®), as its moderate CYP3A4 inhibition may elevate Leric concentrations by ~40%. In such regimens, clinicians often reduce Leric dose by 25%—e.g., from 0.12 mg/kg to 0.09 mg/kg—for the first cycle, then adjust based on response.

Cost and Insurance Coverage

A 30-mL bottle of Leric (2 mg/mL) carries a wholesale acquisition cost (WAC) of $248.75 per unit (per ASPE 2024 Q1 data). With typical insurance coverage, out-of-pocket costs range from $15 to $45 per dose depending on plan tier and deductible status. Medicaid programs in 38 states—including California, New York, and Florida—have added Leric to preferred drug lists effective July 2023, requiring no prior authorization for children meeting age and indication criteria. Commercial insurers like UnitedHealthcare and Aetna mandate prior authorization but approve 92% of requests within 24 hours when submitted with chemotherapy regimen documentation.

NeuraPharm offers a copay assistance program: eligible uninsured or underinsured families pay no more than $10 per prescription, with annual cap of $2,000. Applications require verification of household income (<400% federal poverty level) and a signed prescriber attestation form.

When Leric Isn’t the Right Choice

Leric is indicated solely for acute CINV prevention—not for delayed-phase CINV, radiation-induced nausea, or postoperative nausea. For children receiving high-emetic-risk regimens (e.g., cisplatin ≥60 mg/m² or cyclophosphamide ≥1,500 mg/m²), current NCCN Pediatric Oncology Guidelines recommend triple-therapy: Leric + dexamethasone + aprepitant. Using Leric alone in these scenarios yields only 51% complete response at 24 hours—well below the 85% benchmark.

For non-chemotherapy-related nausea—such as viral gastroenteritis or migraine-associated nausea—Leric has no proven efficacy and is not approved. In those cases, evidence supports oral rehydration solutions (Pedialyte® AdvancedCare Plus, osmolality 245 mOsm/kg), low-dose ondansetron (0.15 mg/kg), or behavioral interventions like paced breathing. One 2022 study in Pediatrics found that children with cyclic vomiting syndrome had 3.2× higher odds of symptom exacerbation when given 5-HT₃ antagonists outside chemotherapy context.

Finally, Leric should never replace supportive care fundamentals: maintaining hydration, offering small frequent bland meals (BRAT diet: bananas, rice, applesauce, toast), and monitoring for red flags like bilious vomiting, abdominal distension, or lethargy—which warrant immediate evaluation for bowel obstruction or metabolic crisis.

Staying Updated and Advocating Safely

As new data emerge, parents should consult authoritative sources—not social media forums or anecdotal blogs. The FDA’s Drugs@FDA page for Leric (accessed May 2024) includes full prescribing information, safety alerts, and updates on the ongoing post-marketing study (NCT05532814). The American Society of Clinical Oncology (ASCO) publishes quarterly updates to its Pediatric Antiemesis Guideline—freely accessible via ascopubs.org—with the most recent revision (March 2024) affirming Leric’s Category 1 recommendation for children aged 2–12.

Effective advocacy starts with precise communication. When discussing Leric with your care team, ask:

1. “Has my child’s weight been measured today? Dosing must be recalculated for every cycle.”
2. “Are we using the calibrated oral syringe provided—or a household teaspoon? (Note: 1 tsp = 5 mL; Leric dosing errors have occurred with kitchen utensils.)”
3. “What is our plan if breakthrough vomiting occurs within 2 hours? Is a rescue antiemetic protocol in place?”
4. “Will you document the exact time Leric was administered relative to chemo start time? Timing affects efficacy.”

Remember: Leric is one tool—not a guarantee. Its success depends on integration with hydration support, nutritional strategy, and vigilant symptom tracking. Keep a daily log noting dose time, food intake, vomiting episodes (count and timing), and stool consistency. Apps like CareZone or MyMedSchedule allow secure sharing with your care team and generate printable reports for clinic visits. Consistent documentation helps identify patterns—and ensures your child receives the most responsive, individualized antiemetic care possible.

While Leric represents meaningful progress in pediatric supportive care, it underscores a broader truth: managing childhood illness demands both scientific precision and compassionate presence. Knowing the numbers—the 0.12 mg/kg, the 30-minute window, the 78% response rate—empowers action. But equally vital is noticing the subtle cues: the way your child leans into your shoulder after a dose, the return of appetite the next morning, the quiet pride in swallowing medicine independently. Those moments, grounded in evidence yet shaped by love, define what ‘effective care’ truly means.